150 related articles for article (PubMed ID: 35379064)
1. Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
He M; Yan W; Zhang Y; Kong Y; Han X; Ren J; Zhao Z; Liu G; Shi J; Li Y
Platelets; 2022 Nov; 33(8):1146-1152. PubMed ID: 35379064
[TBL] [Abstract][Full Text] [Related]
2. Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Galli M; Rollini F; Been L; Zenni MM; Angiolillo DJ; Franchi F
J Thromb Thrombolysis; 2022 Oct; 54(3):461-469. PubMed ID: 36048358
[TBL] [Abstract][Full Text] [Related]
3. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).
Liu GZ; Zhang S; Sun DH; Shi J; Bo WL; Wang WN; Zhang CY; Wang ZH; Feng W; He MJ; Liu YY; Li S; Zheng LQ; Li Y
Eur J Clin Pharmacol; 2019 Aug; 75(8):1059-1068. PubMed ID: 31081522
[TBL] [Abstract][Full Text] [Related]
4. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes.
Liu Z; Tian R; Wang Y; Chen Q; Li J; Xu L; Zhang S
Thromb Haemost; 2020 Aug; 120(8):1221-1229. PubMed ID: 32668483
[TBL] [Abstract][Full Text] [Related]
5. Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Dong Z; Zhai H; Pan L; Zhang B
J Pak Med Assoc; 2021 Feb; 71(2(A)):540-542. PubMed ID: 33819246
[TBL] [Abstract][Full Text] [Related]
6. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Jeong KH; Cho JH; Woo JS; Kim JB; Kim WS; Lee TW; Kim KS; Ihm CG; Kim W
Am J Kidney Dis; 2015 Jun; 65(6):916-24. PubMed ID: 25622774
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors.
Wadowski PP; Pultar J; Weikert C; Eichelberger B; Lang IM; Koppensteiner R; Panzer S; Gremmel T
J Cardiovasc Pharmacol Ther; 2021 May; 26(3):260-268. PubMed ID: 33107322
[TBL] [Abstract][Full Text] [Related]
8. Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy.
Hennigan BW; Good R; Adamson C; Parker WAE; Martin L; Anderson L; Campbell M; Serruys PW; Storey RF; Oldroyd KG
Platelets; 2022 Jan; 33(1):141-146. PubMed ID: 33356730
[TBL] [Abstract][Full Text] [Related]
9. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
10. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
11. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of aspirin vs. clopidogrel in dogs with immune mediated haemolytic anaemia evaluated by serial thromboelastography and platelet mapping.
Griebsch C; Hall E; Barrs VR
Vet J; 2022 Sep; 287():105882. PubMed ID: 35963596
[TBL] [Abstract][Full Text] [Related]
13. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study.
He M; Liu B; Sun D; Pan Y; Zheng W; Shi J; Zhao S; Dong X; Lu S; Li M; Han Y; Li Y
Int J Cardiol; 2016 Jul; 215():209-13. PubMed ID: 27128532
[TBL] [Abstract][Full Text] [Related]
14. Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans.
Infeld M; Friede KA; San TR; Knickerbocker HJ; Ginsburg GS; Ortel TL; Voora D
J Thromb Thrombolysis; 2021 Feb; 51(2):249-259. PubMed ID: 33159252
[TBL] [Abstract][Full Text] [Related]
15. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Abergel E; Nikolsky E
Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Verdoia M; Pergolini P; Rolla R; Sartori C; Nardin M; Schaffer A; Barbieri L; Daffara V; Marino P; Bellomo G; Suryapranata H; De Luca G;
Platelets; 2016 Sep; 27(6):576-82. PubMed ID: 27540959
[TBL] [Abstract][Full Text] [Related]
17. Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Tsoumani ME; Tatsidou PT; Ntalas IV; Goudevenos JA; Tselepis AD
Platelets; 2016 Dec; 27(8):812-820. PubMed ID: 27337147
[TBL] [Abstract][Full Text] [Related]
18. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients.
Gager GM; Jilma B; Winter MP; Hengstenberg C; Lang IM; Toma A; Prüller F; Wallner M; Kolesnik E; von Lewinski D; Siller-Matula JM
Eur J Clin Invest; 2020 Nov; 50(11):e13304. PubMed ID: 32506444
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Verdoia M; Pergolini P; Rolla R; Nardin M; Barbieri L; Schaffer A; Bellomo G; Marino P; Suryapranata H; De Luca G;
Cardiovasc Ther; 2016 Aug; 34(4):209-15. PubMed ID: 27086085
[TBL] [Abstract][Full Text] [Related]
20. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
